Ardelyx rises after new CFO appointment

** Shares of biopharmaceutical company Ardelyx ARDX up 1.93% to $5.03

** Co appoints Sue Hohenleitner as chief financial officer, effective November 4

** Hohenleitner most recently served as the vice president and CFO of Johnson & Johnson Innovative Medicine North America

** Justin Renz, the current CFO, will continue in his role through co's Q3 10-Q filing

** YTD, the stock has fallen ~1%, including session's moves